This is no surrogate marker, this is the big daddy of primaries, the fact that they called it a key secondary only is irrelevant IMO. They have done the largest cellular medicine P3 trial in heart failure and hit it out of the park in my book. The FDA and big pharama will be very interested I predict. EUA could be possible with a confirmatory further P3 paid for by Novartis I hope...
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-191
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |